Savior Lifetec (4167) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Savior Lifetec (4167) has a cash flow conversion efficiency ratio of -0.026x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-98.65 Million ≈ $-3.11 Million USD) by net assets (NT$3.78 Billion ≈ $119.12 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Savior Lifetec - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Savior Lifetec's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Savior Lifetec for a breakdown of total debt and financial obligations.
Savior Lifetec Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Savior Lifetec ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
New Power Plasma Co.Ltd
KQ:144960
|
0.051x |
|
Lucky Cement Co
TW:1108
|
0.039x |
|
Midnight Sun Mining Corp
V:MMA
|
-0.101x |
|
BayWa AG vNa
XETRA:BYW6
|
0.166x |
|
Barings Participation Investors (the Trust)
NYSE:MPV
|
0.033x |
|
Bossa Ticaret ve Sanayi Isletmeleri TAS
IS:BOSSA
|
0.021x |
|
Dynamix Corporation Class A Ordinary Shares
NASDAQ:DYNX
|
-0.005x |
|
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
|
-0.162x |
Annual Cash Flow Conversion Efficiency for Savior Lifetec (2011–2025)
The table below shows the annual cash flow conversion efficiency of Savior Lifetec from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see 4167 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$3.78 Billion ≈ $119.12 Million |
NT$-21.04 Million ≈ $-662.91K |
-0.006x | -103.77% |
| 2024-12-31 | NT$3.52 Billion ≈ $110.78 Million |
NT$518.38 Million ≈ $16.33 Million |
0.147x | +27.87% |
| 2023-12-31 | NT$3.36 Billion ≈ $106.01 Million |
NT$387.95 Million ≈ $12.22 Million |
0.115x | -33.27% |
| 2022-12-31 | NT$3.37 Billion ≈ $106.08 Million |
NT$581.77 Million ≈ $18.33 Million |
0.173x | +440.04% |
| 2021-12-31 | NT$3.31 Billion ≈ $104.37 Million |
NT$-168.34 Million ≈ $-5.30 Million |
-0.051x | -285.45% |
| 2020-12-31 | NT$3.33 Billion ≈ $104.92 Million |
NT$91.25 Million ≈ $2.87 Million |
0.027x | -61.21% |
| 2019-12-31 | NT$2.21 Billion ≈ $69.75 Million |
NT$156.40 Million ≈ $4.93 Million |
0.071x | +169.06% |
| 2018-12-31 | NT$1.86 Billion ≈ $58.47 Million |
NT$-189.84 Million ≈ $-5.98 Million |
-0.102x | -184.82% |
| 2017-12-31 | NT$2.16 Billion ≈ $68.15 Million |
NT$260.89 Million ≈ $8.22 Million |
0.121x | +435.93% |
| 2016-12-31 | NT$2.12 Billion ≈ $66.77 Million |
NT$-76.09 Million ≈ $-2.40 Million |
-0.036x | +86.25% |
| 2015-12-31 | NT$1.59 Billion ≈ $50.15 Million |
NT$-415.82 Million ≈ $-13.10 Million |
-0.261x | -265.61% |
| 2014-12-31 | NT$1.29 Billion ≈ $40.75 Million |
NT$-92.41 Million ≈ $-2.91 Million |
-0.071x | -16.66% |
| 2013-12-31 | NT$1.39 Billion ≈ $43.93 Million |
NT$-85.39 Million ≈ $-2.69 Million |
-0.061x | +65.70% |
| 2012-12-31 | NT$1.27 Billion ≈ $40.16 Million |
NT$-227.59 Million ≈ $-7.17 Million |
-0.179x | +48.89% |
| 2011-12-31 | NT$1.31 Billion ≈ $41.38 Million |
NT$-458.82 Million ≈ $-14.46 Million |
-0.349x | -- |
About Savior Lifetec
Savior Lifetec Corporation, a specialty injectable company, develops, produces, and supplies sterile active pharmaceutical ingredients and finished dosage formulations. The company provides various carbapenem generic drugs and injections, such as paliperidone palmitate, cetrorelix and ganirelix acetate, plecanatide, prucalopride succinate, and brinzolamide. It offers imipenem and cilastatin, mero… Read more